TRAW Stock Overview
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Traws Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.55 |
| Beta | 1.35 |
| 1 Month Change | -15.67% |
| 3 Month Change | 2.31% |
| 1 Year Change | -0.76% |
| 3 Year Change | -94.17% |
| 5 Year Change | -98.86% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Mar 09
Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
Apr 22Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
Jul 27Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
Mar 21Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
Dec 06Onconova Therapeutics names Mark Gelder as chief medical officer
Jun 01Onconova Therapeutics announces $8.7M registered direct offering
Jan 07Onconova cleared to start Phase 1 trial for cancer therapy
Dec 24Onconova Therapeutics EPS in-line, misses on revenue
Nov 12Shareholder Returns
| TRAW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.5% | -2.3% | -3.7% |
| 1Y | -0.8% | 11.4% | 20.2% |
Return vs Industry: TRAW underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: TRAW underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| TRAW volatility | |
|---|---|
| TRAW Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRAW's share price has been volatile over the past 3 months.
Volatility Over Time: TRAW's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 18 | Werner Cautreels | www.onconova.com |
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa.
Traws Pharma, Inc. Fundamentals Summary
| TRAW fundamental statistics | |
|---|---|
| Market cap | US$14.67m |
| Earnings (TTM) | -US$18.95m |
| Revenue (TTM) | US$226.00k |
64.9x
P/S Ratio-0.8x
P/E RatioIs TRAW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRAW income statement (TTM) | |
|---|---|
| Revenue | US$226.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$226.00k |
| Other Expenses | US$19.17m |
| Earnings | -US$18.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,384.07% |
| Debt/Equity Ratio | 0% |
How did TRAW perform over the long term?
See historical performance and comparison